TruSight Tumor 170

Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample. Read More...
选择产品

TruSight Tumor 170 Kit, For Use with NextSeq (24 Samples)

OP-101-1003

TruSight Tumor 170 Kit (24 Samples)

OP-101-1004

TruSight Tumor 170 Kit, For Use with NextSeq plus Watson for Genomics

20018621

TruSight Tumor 170 Kit plus Watson for Genomics

20018622

Product Highlights

TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.

  • Comprehensive Coverage of Cancer-Related Variants
    Assessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications in one assay using DNA and RNA creates efficiencies in sample usage, time, and cost.
  • Accurate Results from Low-Quality Samples1
    Variant detection with as little as 40 ng DNA and RNA input, and as low as 5% mutant allele frequency, maximizes the results from precious formalin-fixed paraffin-embedded (FFPE) samples.
  • Integrated, Streamlined Workflow
    DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis.

Specifications

Method-Specific Workflow Example

 

Scientific Posters

AACR 2017: TruSight Tumor 170 and Tumor Mutational Burden

Results of analysis indicate that TruSight Tumor 170, with comprehensive coverage of cancer-related genes, shows high concordance with whole exome sequencing for accurate assessment of tumor mutational burden.

Learn More

AACR 2017: TruSight Tumor 170 and Solid Tumor Profiling Analytical Performance with FFPE Samples

Standard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85% of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.

Learn More

AACR 2017: TruSight Tumor 170 for Small Nucleotide Variations and Gene Amplifications in FFPE DNA Samples

TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.

Learn More

AACR 2017: TruSight Tumor 170 for Fusions and Splice Variants in FFPE RNA Tumor Samples

Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.

Learn More

Related Products

TruSight Tumor 15

靶向测序panel在同一个简便快速的工作流程中评估15个通常在实体瘤中发生突变的基因。


TruSight RNA Pan-Cancer

靶定1385个癌症基因,用于血液、骨髓及福尔马林固定、石蜡包埋(FFPE)组织等多种RNA样本的基因表达、变异和融合检出研究。


TruSight RNA Fusion Panel

癌症Panel TruSight RNA Fusion Panel靶向RNA测序集合是一项高性价比的解决方案,可检出多种癌症中的基因融合,且该癌症Panel具有识别新融合基因伙伴的功能。


References
  1. Beta study. Data on file. March 2017.